Article info
PDFNeurological rarities
Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy
- Correspondence to Dr Shane Lyons, University Hospital Galway, Galway H91 YR71, Ireland; shane.lyons{at}ndcn.ox.ac.uk
Citation
Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy
Publication history
- Accepted February 22, 2020
- First published April 17, 2020.
Online issue publication
June 02, 2020
Article Versions
- Previous version (2 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
- Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
- Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
- Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- Central nervous system complications associated with immune checkpoint inhibitors
- Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
- Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
- Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy